- Research
The new Spin-off Ahead Therapeutics SL, will develop new therapies for auto-immune diseases
The spin-off is the result of a joint research project between the IGTP, ICN2 and ICREA and has already attracted 1.1 million euros. The Catalan biotech company has been created to develop the therapies for clinical use. The therapy uses liposomes to halt the destructive reaction of the body's own tissues caused by diseases such as Type 1 diabetes or multiple sclerosis.